TG Therapeutics (FRA:NKB2) Ending Cash Position : €123.4 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Ending Cash Position?

TG Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2025 was €123.4 Mil.

TG Therapeutics's quarterly Ending Cash Position declined from Sep. 2024 (€177.6 Mil) to Dec. 2024 (€173.0 Mil) and declined from Dec. 2024 (€173.0 Mil) to Mar. 2025 (€123.4 Mil).

TG Therapeutics's annual Ending Cash Position declined from Dec. 2022 (€97.8 Mil) to Dec. 2023 (€86.4 Mil) but then increased from Dec. 2023 (€86.4 Mil) to Dec. 2024 (€173.0 Mil).

TG Therapeutics Ending Cash Position Historical Data

The historical data trend for TG Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Ending Cash Position Chart

TG Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

455.96

265.63

97.78

86.40

173.04

TG Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															70.63	78.22	177.60	173.04	123.43

TG Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TG Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	89.978	+	83.06
	=	173.0

TG Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	167.602	+	-44.169
	=	123.4

TG Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

TGTX:USA 0VGI:UK

Address

3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines